Clinical Trials | February 14, 2026
Precision BioSciences cleared by FDA to launch groundbreaking Duchenne gene editing trial
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
